These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11758295)

  • 1. A method for assessing the cost-effectiveness and the break-even point of clinical practice guidelines.
    Gandjour A; Lauterbach KW
    Int J Technol Assess Health Care; 2001; 17(4):503-16. PubMed ID: 11758295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management, part I: introduction and general considerations.
    Manchikanti L
    Pain Physician; 2008; 11(2):161-86. PubMed ID: 18354710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to assessing the health benefit from obesity interventions in children and adolescents: the assessing cost-effectiveness in obesity project.
    Haby MM; Vos T; Carter R; Moodie M; Markwick A; Magnus A; Tay-Teo KS; Swinburn B
    Int J Obes (Lond); 2006 Oct; 30(10):1463-75. PubMed ID: 17003807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
    Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
    Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pressure ulcers: guideline development and economic modelling.
    Legood R; McInnes E
    J Adv Nurs; 2005 May; 50(3):307-14. PubMed ID: 15811110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a family-based GP-mediated intervention targeting overweight and moderately obese children.
    Moodie M; Haby M; Wake M; Gold L; Carter R
    Econ Hum Biol; 2008 Dec; 6(3):363-76. PubMed ID: 18657487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of nutritional counseling for obese patients and patients at risk of ischemic heart disease.
    Olsen J; Willaing I; Ladelund S; Jørgensen T; Gundgaard J; Sørensen J
    Int J Technol Assess Health Care; 2005; 21(2):194-202. PubMed ID: 15921059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Developing evidence based guidelines on cardiac rehabilitation - phase 1: a qualitative review].
    Bitzer EM; Aster-Schenck IU; Klosterhuis H; Dörning H; Rose S
    Rehabilitation (Stuttg); 2002 Aug; 41(4):226-36. PubMed ID: 12168147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Practice guidelines in rehabilitation: infringement upon physicians' autonomy or foundation for better outcomes?].
    Brüggemann S; Korsukéwitz C
    Rehabilitation (Stuttg); 2004 Oct; 43(5):304-11. PubMed ID: 15472789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.